Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug Interactions
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 56 (1) , 15-23
- https://doi.org/10.2165/00003495-199856001-00003
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Inter‐ethnic comparisons of the pharmacokinetics of the HMG‐CoA reductase inhibitor cerivastatinBritish Journal of Clinical Pharmacology, 1998
- Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*Clinical Pharmacology & Therapeutics, 1998
- Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatinEuropean Journal of Clinical Pharmacology, 1998
- In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.1997
- Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses*Clinical Pharmacology & Therapeutics, 1997
- Influence of cholestyramine on the pharmacokinetics of cerivastatin.1997
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitorsAmerican Journal of Health-System Pharmacy, 1995
- Macrolide AntibacterialsDrug Safety, 1995
- Biotransformation of lovastatinArchives of Biochemistry and Biophysics, 1991